Protagenic Financial Statements From 2010 to 2026

PTIX Stock  USD 0.54  0.03  5.26%   
Protagenic Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Protagenic Therapeutics' valuation are provided below:
Market Capitalization
1.4 M
Earnings Share
(13.13)
We have found one hundred twenty available trending fundamental ratios for Protagenic Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Protagenic Therapeutics recent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road.
Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 43 K, Interest Expense of 0.0 or Selling General Administrative of 1.5 M, as well as many indicators such as Price To Sales Ratio of 3.0E-4, Dividend Yield of 0.0 or PTB Ratio of 31.35. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Protagenic Stock
Check out the analysis of Protagenic Therapeutics Correlation against competitors.
For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.

Protagenic Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.7 M1.8 M2.2 M
Slightly volatile
Short and Long Term Debt Total294.3 K309.8 K737.6 K
Slightly volatile
Other Current Liabilities718 K755.8 K545.1 K
Slightly volatile
Total Current Liabilities806.1 K848.5 K1.7 M
Pretty Stable
Cash1.9 M1.7 M814.6 K
Slightly volatile
Cash And Short Term Investments3.9 M2.1 M2.3 M
Slightly volatile
Common Stock Shares Outstanding5.4 M5.6 M202 M
Slightly volatile
Liabilities And Stockholders Equity1.7 M1.8 M2.9 M
Very volatile
Other Current Assets38 K40 K127.2 K
Very volatile
Other Stockholder Equity42.8 M43.1 M39.2 M
Pretty Stable
Total Liabilities806.1 K848.5 K1.9 M
Pretty Stable
Total Current Assets1.6 M1.7 M2.2 M
Slightly volatile
Common Stock620652118.8 K
Slightly volatile
Accounts Payable88 K92.7 KM
Slightly volatile
Capital Stock733652942
Slightly volatile

Protagenic Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization43 K45.3 K74.8 K
Slightly volatile
Selling General Administrative1.5 M1.6 M1.3 M
Slightly volatile
Other Operating Expenses4.9 M5.1 MM
Slightly volatile
Selling And Marketing Expenses30.8 K32.5 K73.1 M
Slightly volatile
Research Development4.6 M4.4 M1.4 M
Slightly volatile
Interest Income71.7 K50 K42 K
Slightly volatile
Reconciled Depreciation60.7 K57.8 K10.2 K
Slightly volatile

Protagenic Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.1 M1.5 M805 K
Slightly volatile
Depreciation43 K45.3 K35.3 K
Slightly volatile
End Period Cash Flow1.9 M1.7 M814.3 K
Slightly volatile
Stock Based Compensation880.1 K1.1 M692.2 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.0E-43.0E-4445.4 K
Slightly volatile
Days Sales Outstanding94.4456.9554.9188
Very volatile
Average Payables205.3 K195.5 K94.7 K
Slightly volatile
Stock Based Compensation To Revenue0.02630.0250.0239
Slightly volatile
Capex To Depreciation4.544.78624
Slightly volatile
Inventory Turnover1.181.41.5095
Pretty Stable
Days Of Inventory On Hand278270242
Pretty Stable
Payables Turnover0.530.560.2969
Pretty Stable
Sales General And Administrative To Revenue0.190.234.7755
Slightly volatile
Capex To Revenue0.00110.00120.0123
Slightly volatile
Cash Per Share0.410.431.7116
Pretty Stable
Days Payables Outstanding639673249.2 K
Slightly volatile
Income Quality0.940.880.5774
Slightly volatile
Intangibles To Total Assets0.190.180.1712
Slightly volatile
Current Ratio2.461.83.0283
Slightly volatile
Receivables Turnover3.616.636.9133
Very volatile
Capex Per Share0.03770.03960.0455
Slightly volatile
Revenue Per Share376.4 K353.2 K319.9 K
Slightly volatile
Interest Debt Per Share0.02710.02851.9557
Slightly volatile
Debt To Assets0.03660.03850.9563
Slightly volatile
Operating Cycle54.1156.9569.344
Slightly volatile
Days Of Payables Outstanding639673249.2 K
Slightly volatile
Ebt Per Ebit0.570.871.0311
Slightly volatile
Quick Ratio2.21.83.013
Slightly volatile
Net Income Per E B T0.780.91.1494
Slightly volatile
Cash Ratio1.841.761.259
Pretty Stable
Days Of Inventory Outstanding278270242
Pretty Stable
Days Of Sales Outstanding94.4456.9554.9188
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.361.21.0386
Slightly volatile
Fixed Asset Turnover12.7113.3839.5 K
Slightly volatile
Debt Ratio0.03660.03850.9563
Slightly volatile
Price Sales Ratio3.0E-43.0E-4445.4 K
Slightly volatile
Asset Turnover0.941.861.6412
Slightly volatile

Protagenic Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap11 K11.6 K202.2 K
Slightly volatile

Protagenic Fundamental Market Drivers

Protagenic Upcoming Events

13th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Protagenic Therapeutics Financial Statements

Protagenic Therapeutics investors use historical fundamental indicators, such as Protagenic Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue(359.19)(341.23)
Cost Of Revenue45.3 K43 K
Stock Based Compensation To Revenue 0.03  0.03 
Sales General And Administrative To Revenue 0.20  0.19 
Revenue Per Share353.2 K376.4 K
Ebit Per Revenue(0.64)(0.67)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.